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Abstract: Isatin and its metabolites are constituents of many natural substances. They are also 
components of many synthetic compounds exhibiting a wide range of effects, including antiviral 
activity, antitumor and antiangiogenic activity, antibacterial, antitubercular, antifungal, antiap-
totic, anticonvulsant and anxyolytic activities. Isatin itself is an endogenous oxidized indole with a 
wide spectrum of behavioral and metabolic effects. It has a distinct and discontinuous distribution 
in the brain, peripheral tissues and body ﬂ  uids and isatin binding sites are widely distributed also. 
Its output is increased during stress. Its most potent known in vitro actions are as an antagonist 
of atrial natriuretic peptide (ANP) function and NO signaling. As we understand more about its 
function and sites of action we may be able to develop new pharmacological agents to mimic 
or counteract its activity. We consider here the most promising biological targets for various 
isatin analogues and/or metabolites, which are employed for the development of various groups 
of therapeutics. It is also possible that the level of endogenous isatin may inﬂ  uence the in vivo 
pharmacological activity of compounds possessing the isatin moiety.
Keywords: isatin, isatin analogues, isatin binding proteins, isatin targets, biological and phar-
macological activity
Introduction
Endogenous compounds are often used as a basis, or structural component, of 
pharmacological preparations. For example indirubin is the active ingredient of Danggui 
Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat 
chronic diseases (Hoessel et al 1999) and also individual Chinese medicinal herbs Isatis 
indigotica and Strobilanthes cusia (Mak et al 2004). Indirubin derivatives are potent 
inhibitors of cyclin dependent kinases and some other pharmacologically important 
kinases. Indirubin may be formed during dimerization of isatin (Figure 1), another 
biologically active compound, which attracts much interest of pharmacologists. Isatin 
(indoledione 2, 3) is an endogenous indole found in the mammalian brain, peripheral tis-
sues and body ﬂ  uids (see for review Medvedev et al 1996; Glover et al 1998; Medvedev 
and Glover 2004; Medvedev, Igosheva et al 2005). The isatin moiety is also present in a 
range of compounds which can act as inhibitors of apoptosis (Lee et al 2001; Chapman 
et al 2002), anticonvulsants (Verma et al 2004), and other antiviral (Sriram et al 2004; 
Pirrung et al 2005), anti-bacterial and anti-fungal (Chohan et al 2004) agents. It is possible 
that drugs containing the isatin moiety, may compete with endogenous isatin, and the 
latter can inﬂ  uence their therapeutic effect. Consequently, analysis of the isatin content 
of the body, its metabolic routes, and its interactions may not only be of importance 
for understanding more about the function of this endogenous regulator, but also for 
understanding its possible role as a functional agonist/antagonist of drugs.
In this review we discuss the wide range of biological targets that are known to 
be sensitive to isatin and its analogues and the evidence that endogenous isatin may 
affect their responsivity.Biologics: Targets & Therapy 2007:1(2) 152
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Metabolism
Isatin was originally identiﬁ  ed as one component of the 
endogenous monoamine oxidase (MAO) inhibitory activity, 
tribulin (Glover et al 1988). The isatin concentration in blood 
can exceed 1 μM (Manabe et al 1997; Mawatari et al 2001; 
Igosheva et al 2004). Based on tissue isatin (Watkins et al 
1990) and water (Reinoso et al 1997) content calculations, 
basal isatin tissue concentrations are different in various 
organs (Table 1). Highest concentrations in the brain are 
in hippocampus, cerebellum and striatum (1–1.3 μM), 
whereas in peripheral organs the highest concentrations are 
in seminal vesicles and vas deferens: 47.4–79 μM. In the 
heart the maximal basal concentration approaches to 3 μM. 
In other rat organs basal isatin concentrations vary from 
0.3 μM (spleen) to 1.5 μM (liver). In the rat, stress causes 
the 2–3 fold increase of isatin content in the brain and heart 
(Igosheva et al 2004), 2.5–6 fold increase of isatin output 
in urine (Tozawa et al 1998), and its concentration in serum 
reaches 2.9 ± 0.29 μM (Igosheva et al 2004). This suggests 
that under certain conditions isatin concentrations may be as 
high as 10 μM and even more (if we take into consideration 
exceptionally high concentrations in seminal vesicles and 
vas deferens).
Although the pathways of endogenous isatin formation 
(see Figure 1) still require better experimental support 
there is in vitro evidence that isatin can be formed from 
indole, typically produced by tryptophan catabolism in 
the gut, and that this involves microsomal cytochrome 
P450 (Gillam et al 2000). Besides excretion with urine, 
the catabolic pathways of isatin include further, possibly 
spontaneous, oxidation and dimerization yielding the 
indigoid pigments, indigo and indirubin (Medvedev et al 
1996; Gillam et al 2000), hydrogen peroxide-dependent 
conversion into anthranilic acid (Medvedev and Glover 
2004) and NADPH-dependent reduction to 3-hydroxy-
2-oxoindole (Usami et al 2001). All these compounds 
have been found in urine (Usami et al 2001; Medvedev 
and Glover 2004). However, it remains unclear whether 
indigoid formation precedes urinary excretion and aerobic 
transformation of the urinary components. Interestingly, 
during in vitro oxidation of indole by cytochrome P450 
enzymes, isatin was an intermediate, which was then 
O
O
O
O
O
O
O
O O
OH
NH2 N
N
H
H
N
N
H
H
OH
anthranilic
acid
3-hydroxy-
2-oxoindole
indirubin
indigo
indoxyl
isatin
indole
N N
H H
N
N
H
H
Figure 1 Scheme of isatin origin and metabolism (modiﬁ  ed from Medvedev et al 1996).Biologics: Targets & Therapy 2007:1(2) 153
Biological targets for isatin and its analogues
transformed into the indigoid pigment major end products 
(Gilliam et al 2000).
The study of isatin content in conventional and germ-free 
rats has shown that at least for basal isatin, urinary but not tis-
sue levels are largely produced by the gut ﬂ  ora. Urinary isatin 
levels in germ free rats are 50 times lower than in samples 
from conventional rats, but both have similar concentrations 
in tissues (Sandler et al 1991). This suggests that gut ﬂ  ora 
do have an important role in the production of urinary isatin, 
at least in the rat.
Biological targets
Distribution of isatin-binding sites
Several lines of experimental evidence suggest the existence 
of multiple binding sites for isatin in the brain and other 
tissues. [3H]isatin imaging in situ has shown the pattern 
of isatin-binding sites in different parts of the rat brain 
(Crumeyrolle-Arias et al 2003). The highest labeling was 
found in hypothalamic nuclei, in the cortex, the hippo-
campus, and the cerebellum. Administration of the MAO 
inhibitor, pargyline, to rats caused some reduction, but did 
not abolish the [3H]isatin-binding (Crumeyrolle-Arias et al 
2003). This suggests that MAO is one of the isatin-binding 
sites in situ. Indeed, this has been demonstrated using high-
resolution crystal structures of recombinant MAO B with 
isatin and its tight binding led to an improved crystal quality 
(Binda 2003). Other putative isatin binding sites in the rat 
brain include atrial natriuretic peptide (ANP) and C-type 
natriuretic peptide, which inhibit [3H]isatin-binding to rat 
brain sections and isolated membrane fractions (Medvedev, 
Crumeyrolle-Arias et al 2005). These results suggest that 
some [3H]isatin-binding in the brain may be to the natriuretic 
peptide receptors (NPR) (Medvedev, Crumeyrolle-Arias 
et al 2005). Using an optical biosensor technique isatin-
binding sites have been demonstrated in both particulate 
and soluble fractions of the brain and peripheral rat tissues 
(Ivanov et al 2002; Medvedev and Glover 2004). In the 
brain isatin-binding predominated in the membrane fraction, 
whereas in the kidneys the highest binding was observed in 
the soluble fractions. The distribution of isatin-binding sites 
in the particulate fraction reduced in the following order: 
brainstem  brain hemispheres = cerebellum  heart  
kidneys  liver. In the soluble fraction there was a different 
rank of isatin-binding.
There are biological targets that speciﬁ  cally bind isatin and 
also those sensitive to inhibition by physiologically relevant 
concentrations of isatin. The former group includes MAO, 
the cytosolic enzymes glycerol-3-phosphate dehydrogenase 
(Buneeva et al 2003), glyceraldehyde-3-phosphate dehydro-
genase (Panova et al 2002, Medvedev et al 2006), pyruvate 
kinase (Buneeva et al 2006), and ubiquitin (Buneeva et al pre-
pared for publication). Other isatin binding proteins detected 
in both soluble and particulate fractions of various tissues 
using optical biosensor technique (Ivanov et al 2002) require 
detailed investigation and identiﬁ  cation (Buneeva et al in 
preparation).
Isatin-binding proteins
Pyruvate kinase (PK; EC 2.7.1.40) is an important glycolytic 
enzyme, which catalyses the reaction of a phosphoryl group 
transfer from phosphoenolpyruvate to ADP in the reac-
tion of substrate phosphorylation: Phosphoenolpyruvate + 
ADP → (Enol)pyruvate + ATP. Rabbit muscle pyruvate 
kinase (this isoform is also present in the brain (Tsutsumi 
et al 1988; Yamada and Noguchi 1999)) did bind isatin 
and the Kd value of 10 μM was at the upper physiological 
range of isatin concentrations (Buneeva et al 2006). This 
interaction appeared to be speciﬁ  c as the other enzyme of 
this class, creatine kinase (EC 2.7.3.2) did not exhibit con-
centration dependent binding of [3H]isatin (Buneeva et al 
2006). Pyruvate kinase interaction with isatin was sensitive 
to inhibition by ATP (IC50 of 25 μM) and by a neuroprotec-
tive preparation, deprenyl (IC50 of 5 μM). Although the 
biological role of this interaction is not fully understood, it 
may be that this phenomenon underlies some non-glycolytic 
functions of this enzyme (Buneeva et al 2006). Indeed 
certain evidence exists that pyruvate kinase is the factor 
Table 1 Concentrations of isatin in brain and some other tissues 
of the rat
Tissue   Range of isatin concentrations, μM 
Whole brain   0.3–0.4 
Hippocampus   0.9–1.3
Cerebellum   0.8–1.2
Striatum 0.6–1.0 
Heart 0.79–2.62
Liver 0.77–1.45
Kidney 0.88–1.32
Lung   0.14–1.20
Spleen 0.35–0.62
Testes 0.16–0.63
Seminal vesicles  2.37–47.4*
Vas deferens  1.58–79.0*
Calculations have been made using data on tissue isatin content (Watkins et al 
1990; see also Medvedev et al 1996) and water content in various tissues of the rat 
(Reinoso et al 1997).
*Due to lack of data available on water content in vas deferens and seminal vesicles 
isatin concentrations have been calculated using data on water content in testes 
(0.861 ml/g) (Reinoso et al 1997).Biologics: Targets & Therapy 2007:1(2) 154
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of regulation of cytoskeletal proteins (Vértessy et al 1999; 
Kovács et al 2003), it is also involved in resistance of glial 
cells to hypoxia (Shimizu et al 2004).
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; EC 
1.2.1.12) is a classical glycolytic enzyme, exhibiting diverse 
nonglycolytic functions in dependence of its subcellular 
localization. GAPDH speciﬁ  cally interacts with different 
RNAs in vivo and in vitro (Nagy and Rigby 1995; De et al 
1996; Lin et al 2000; Yi et al 2000; Evguenieva-Hackenberg 
et al 2002) and may cleave some of them (Evguenieva-
Hackenberg et al 2002). Overexpression of GAPDH and 
its subsequent nuclear translocation are implicated in the 
initiation of one or more apoptotic cascades and also in the 
aetiology of some neurological diseases (Tatton et al 2003; 
Berry 2004). The translocation of GAPDH into the nucleus 
can be an important event leading to apoptosis (Tatton et al 
2003; Berry 2004), especially in neuronal cells.
There is increasing evidence that GAPDH may serve 
as a target for small-molecule anti-apoptotic compounds 
slowing/preventing progression of neurodegenerative 
disorders (Ishitani et al 2003; Berry 2004). GAPDH is thus a 
promising target for various neuroprotective drugs and good 
evidence now exists that the binding of deprenyl (initially 
introduced as a mechanism-based MAO B inhibitor) and 
other propargylamines to GAPDH is primarily responsible 
for the neuroprotective and antiapoptotic effects of these 
substances (Carlile et al 1998; Kragten et al 1998; Maruyama 
et al 2001; Tatton et al 2003; Berry 2004).
Besides these pharmacological substances GAPDH can 
also bind isatin (Medvedev et al 2006) with Kd values (of 
12 and 3.1 μM, determined by two independent methods 
respectively), which are within the upper physiological limit 
of isatin concentrations. Such interaction was relatively spe-
ciﬁ  c because another oligomeric cytosolic NAD-dependent 
enzyme, lactate dehydrogenase, did not bind to the immo-
bilized isatin analogue (Medvedev et al 2006). Binding of 
GAPDH to isatin only weakly inﬂ  uenced the glycolytic 
activity of this enzyme but inhibited GAPDH-mediated 
cleavage of E. coli tRNA.
Glycerol-3-phosphate dehydorgenase (GPDH)
Highly puriﬁ  ed rabbit muscle GPDH effectively binds to the 
isatin analogue immobilised on the cuvette of IAsys optical 
biosensor (Buneeva et al 2003). Replacement of the cuvette 
medium for washing buffer did not cause total dissociation 
of GPDH-isatin complexes. This suggests involvement of 
several types of enzyme-isatin interaction including tight 
binding. Although 10 μM and 100 μM concentrations of 
isatin caused different effects on GPDH activity: the former 
signiﬁ  cantly increased apparent Km for NAD, whereas the 
latter decreased apparent Vmax and increased Km, – possible 
biological signiﬁ  cance of this regulation remains unclear.
Ubiquitin
Ubiquitin is a highly conserved 8 kDa protein, which is 
covalently attached to lysine residues of target proteins by the 
ubiquitin conjugation system. This metabolic pathway is often 
used for the selective proteasome degradation of many short-
lived proteins in eukaryotic cells. The ubiquitin-mediated 
degradation of regulatory proteins plays important roles 
in the control of numerous processes, including cell-cycle 
progression, signal transduction, transcriptional regulation, 
receptor down-regulation, and endocytosis (Hershko and 
Ciechanover 1998). The ubiquitin system is involved into the 
immune response, development, programmed cell death, and 
abnormalities in ubiquitin-mediated processes may be a cause 
for development of various pathological conditions, including 
malignant transformation (Hershko and Ciechanover 1998; 
Hoeller et al 2006), systemic lupus erythematosus (Jury 
et al 2003) and other autoimmune diseases (Jiang et al 2004), 
Parkinson’s disease (Dawson 2006, Buneeva and Medvedev 
2006), etc.
We have recently demonstrated that ubiquitin binds to an 
isatin analogue immobilized at the Biacore cell (Buneeva et al 
in preparation). Although the Kd value of 0.27 mM is rather 
high, this phenomenon may have implications for ubiquitin 
interaction with isatin analogues (see below).
Biological targets sensitive to inhibition 
by isatin
Table 2 summarizes current knowledge of the effects of 
physiological concentrations of isatin on molecular targets 
in vitro. The most sensitive in vitro targets for isatin are the 
ANP signaling system, which includes ANP receptor binding, 
ANP receptor coupled particulate guanylate cyclase (natri-
uretic peptide receptor type A, NPR-A) (Glover et al 1995; 
Medvedev et al 1998; Medvedev, Igosheva et al 2005), solu-
ble NO stimulated guanylate cyclase (Medvedev et al 2002), 
and MAO B (Medvedev and Glover 2004). They are sensitive 
to ﬂ  uctuations of physiological concentrations of isatin. 
Although other targets listed in this Table 1 exhibit rather 
low sensitivity to the highest physiological concentration of 
isatin it is possible that using isatin moiety as a lead structure Biologics: Targets & Therapy 2007:1(2) 155
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Table 2 Molecular targets sensitive to physiological concentrations of isatin (modiﬁ  ed from Glover et al 1995; Medvedev,
Igosheva et al 2005)
Inhibition 50% caused by  Inhibition 50% caused by  Inhibition 20%–40% caused by  Inhibition 20% caused by 
1 μM isatin  10 μM isatin  10 μM isatin  10 μM isatin
Receptor binding:  Enzyme activity:  Neurotransmitter receptor binding:  Neurotransmitter receptor binding:
[121I]ANP- receptor  Natriuretic   NMDA receptor AMPA receptor  Adenosine-1, adenosine-2; α -1 , α-2, β-ad-renergic;
binding  peptide receptor  Dopamine D4-receptor  dopamine-1, dopamine-2; GABA A, GABA B;
  (NPR-A) coupled  Muscarinic (M-2) receptor  histamine-I, histamine-2, histamine-3; 5-HT-1,
  guanylate cyclase  Glycine (strychnine sensitive)  S-HT-2, 5-HT-3; muscarinic-1, muscarinic-3; nicotinic;
  MAO B  receptor  kainic acid; glycine (strychnine insensitive);
    opiate  (σ, μ, κ).
Enzyme activity:   Growth factor receptor  Brain and gut peptides and growth factor
NO-stimulated   binding: Epidermal  receptor binding:
guanylate cyclase    growth factor receptor  Angiotensin II, type 2; vasopressin-I; bombesin;
    CCKA; CCKB endothelin B; substance P; 
       neuropeptide Y; neurotensin; somatostatin;
      vasoactive intestinal peptide; nerve growth factor, 
    NPR-C
  Ion channel binding:  Ion channel binding: Chloride; sodium; potassium;
  Potassium  channel  calcium
  Other targets: Inositol  Uptake site binding: Adenosine; choline; dopamine;
     triphosphate Protein kinase C  GABA; noradrenaline; 5-HT.
  Enzyme activity:  Other targets: Forskolin; leukotriene B4,
    MAO A  leukotriene D4; thromboxane A2, ERK
it would be possible to obtain pharmacologically attractive 
compounds acting as effective inhibitors of these regulatory 
systems. There are many examples, when the presence of var-
ious substituents in the isatin moiety signiﬁ  cantly increased 
biological activity to particular targets (see below).
Atrial natriuretic peptide signaling system
The natriuretic peptides are a family of related compounds, 
including atrial natriuretic peptide (ANP), brain natriuretic 
peptide (BNP), and C-type natriuretic peptide (CNP). These 
peptides and their receptors represent an important regulatory 
system (Anand-Srivastava and Trachte 1993; Potter et al 
2006), involved not only in the regulation of ﬂ  uid homeosta-
sis and blood pressure, but also into regulation of emotional 
behavior (eg, anxiety and arousal) and in altered stress 
hormone release and autonomic nervous system activation 
(Wiedemann et al 2000). Natriuretic peptides interact with 
three types of membrane receptor. Two of them, natriuretic 
peptide receptor type A (NPR-A) and natriuretic peptide 
receptor type B (NPR-B), are transmembrane glycoproteins 
exhibiting ligand-dependent intrinsic guanylyl cyclase activ-
ity (Anand-Srivastava and Trachte 1993; Silberbach and 
Roberts 2001; Misono 2002; Trachte 2005; Potter et al 2006). 
ANP and BNP bind preferentially to NPR-A, whereas CNP 
exhibits much higher afﬁ  nity for NPR-B. The third receptor, 
natriuretic peptide receptor type C (NPR-C), lacks the cyclase 
domain and binds all three peptides. NPRC receptors are 
coupled to adenylyl cyclase inhibition through inhibitory 
guanine nucleotide-regulating protein (Anand-Srivastava and 
Trachte 1993; Silberbach and Roberts 2001; Misono 2002; 
Trachte 2005; Potter et al 2006).
Isatin inhibited [125I]ANP binding to guinea pig cerebellar 
membranes (Glover et al 1995) and the IC50 of 0.4 μM is within 
the lower limit of the physiological range of isatin concen-
trations (0.3–1.3 μM). ANP and CNP inhibited [3H]isatin-
binding to rat brain sections and isolated membrane fractions 
and the IC50 value for the ANP effect (0.2 μM) (Medvedev, 
Crumeyrolle-Arias et al 2005) was very close to the corre-
sponding effect of isatin on ANP binding. Isatin also inhibited 
rat brain particulate guanylyl cyclase activity stimulated by 
ANP and BNP (Medvedev et al 1998). This suggests the 
involvement of NPR-A. Recently, it has been reported that 
isatin in situ blocks the effect of ANP on hyperpolarization-
activated current in human atrial myocytes involving cyclic 
GMP signaling (Lonardo et al 2004). The latter provides 
further experimental evidence for isatin interaction with 
NPR-A. Isatin administration blocked cyclic GMP excretion 
under conditions of ﬂ  uid overload, which is known to induce 
endogenous ANP release (Medvedev et al 2001). This provides 
evidence that isatin can antagonise NPR-A signaling in vivo. 
Indeed perfusion with 10 μM isatin administration aborted 
the protective effect of atrial natriuretic peptide administered 
just prior to reperfusion evaluated by limited infarction in 
rabbit hearts (Yang et al 2006). Isatin administration has been Biologics: Targets & Therapy 2007:1(2) 156
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shown to block cyclic GMP excretion under conditions of ﬂ  uid 
overload, which is known to induce endogenous ANP release 
(Medvedev et al 2001). This provides further evidence that 
isatin can antagonise NPR-A signaling in vivo.
At high concentrations (100 μM) isatin may also 
inhibit natriuretic peptide signaling associated with NPR-C 
(Medvedev, Crumeyrolle-Arias et al 2005). This is consis-
tent with isatin inhibition of ANP, BNP and CNP-induced 
behavioral effects (Bhattacharya et al 1996a, 1996b; Telegdy 
et al 2000; Pataki et al 2000), because the three major natri-
uretic peptides only act in common at one type of natriuretic 
peptide receptor type C, NPR-C (Anand-Srivastava and 
Trachte 1993; Silberbach and Roberts 2001; Misono et al 
2002; Potter et al 2006).
Potter et al (2004) have reported that pretreatment with 
isatin (100 μg bilaterally) abolished the effect of brem-
azocine, a κ-opioid receptor agonist, causing enhanced total 
outﬂ  ow facility by enhancing levels of natriuretic peptide 
(ANP, BNP, CNP) in aqueous humor. This is further evi-
dence suggesting that isatin antagonizes natriuretic peptide 
receptors in situ and in vivo.
Nitric oxide stimulated soluble guanylate cyclase
Besides membrane bound gualylate cyclase coupled to 
natriuretic peptide receptors the soluble guanylate cyclase 
is the other enzyme catalyzing cGMP formation from GTP. 
The enzyme is activated by NO (formed from L-arginine by 
nitric oxide synthase) and various NO donors including those 
employed clinically (Luscher 1992; Keefer 2003; Napoli 
and Ignarro 2003). The enzyme plays an important role in 
vasodilation (Ignarro et al 1999; Ignarro 2002). It has been 
shown that basal activity of the human platelet guanylate 
cyclase is not sensitive to isatin whereas the NO-stimulated 
activity is inhibited by low physiological concentrations of 
isatin (in the 10–8 to 10–6 M range) (Medvedev et al 2002). 
Subsequent increase of isatin concentration was accompanied 
by clear decrease of its effect.
The unidirectional regulation of particulate (NPR-A) 
and soluble guanylate cyclases by different range of isatin 
concentration is suggested to be important for stress-induced 
switch in metabolic processes sensitive to cGMP-dependent 
control (Medvedev et al 2002).
Extracellular signal regulated protein kinase (ERK)
This enzyme existing as ERK1 and ERK2 isoforms is activated 
via phosphorylation and the activated ERK phosphorylates 
cytoplasmic, membrane and nuclear substrates required for 
sequential transition of cell cycle phases (particularly G1/S 
and G2/M transitions) (Chambard et al 2007). Treatment 
of cells with 60–100 μM isatin reduced ERK activity and 
signiﬁ  cantly reduced phosphrylation of the EKR2 isoform 
(Cane et al 2000).
Cell cultures
Isatin can induce cell death, including apoptosis in some 
tumor cells. However, molecular targets responsible for this 
effect remain unknown. Igosheva et al (2005) have shown 
that isatin (50–100 μM) increased apoptosis in dopaminergic 
neuroblastoma SH-SY5Y cells. At higher isatin concentra-
tions the cells died via necrosis. Cane et al (2000) observed 
antiproliferative effect of isatin in both tumor (human promy-
elocytic leukemia HL60 cells, rat adrenal pheochromocytoma 
PC12 cells, mouse N1E-115 neuroblastoma cells) and normal 
cells (mouse ﬁ  broblast BALB/c3T3 cells, bovine brain capil-
lary BBC cells). The effective concentration, required for a 
50% effect was at the upper limits of physiological concen-
trations or higher (10–50 μM). In both these studies the cells 
were cultured with low serum concentrations as a source 
of growth factors and it remains to be determined whether 
normal and/or tumor cells would be similarly vulnerable.
Isatin (10–100 μM) inhibited nitric oxide production 
by RAW 264.7 macrophage cells activated by a mixture 
of lipopolysaccharide (LPS) and interferon γ in a dose 
dependent manner. It also inhibited production of pros-
taglandin E2 (PGE2) and tumor necrosis factor (TNF-α) 
(Matheus et al 2007). The inhibition of NO and PGE2 
production in LPS-INF-γ is obviously associated with the 
isatin effect on expression of inducible nitric oxide synthase 
and cyclooxygenase-2 (COX-2) respectively, as it has 
been demonstrated by a Western blot analysis (Matheus 
et al 2007).
Isatin metabolites and analogues 
and their effects on biological 
targets
Isatin and its metabolites are constituents of natural sub-
stances and also components of synthetic compounds 
exhibiting: antiviral activity (Mak et al 2004), antitumor 
and antiangiogenic activity (Pandeya et al 2005; Cerchiaro 
and da Costa Ferreira 2006), antibacterial, antitubercular, 
antifungal (Chohan et al 2004; Pandeya et al 2005), and 
other activities. Some of them are effective anticonvul-
sants and anxyolytics (Pandeya et al 2005). The speciﬁ  c 
biological targets responsible for these diverse effects are 
not all known. However there are several speciﬁ  c targets, Biologics: Targets & Therapy 2007:1(2) 157
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which have attracted considerable attention in relation to 
the regulatory or pharmacological effects of isatin and its 
metabolites and analogues.
Proteases
Isatin analogues possessing various substituents at R-R''' 
and R''''' (see Figure 2) were active against SARS coro-
navirus 3CL protease (belonging to the family of serine 
proteases), an important target for design of drugs for treat-
ment of a new viral atypical pneumonia, known as severe 
acute respiratory syndrome (SARS). The IC50 values were 
within the concentration range from 0.95 to 17.50 μM (Chen 
et al 2005). The effect of the most active compound tested 
was highly speciﬁ  c: inhibition of other serine proteases 
(trypsin, chymotrypsin) and papain (cysteine protease) was 
observed at much higher concentrations (10 μM–1 mM) 
(Chen et al 2005).
N-substituted isatin derivatives (but not isatin itself  ) 
inhibited parasitic cysteine proteases identified in try-
panosomes (cruzain and rhodesain) and malaria parasites 
(falcipain-2) (Chiyanzu et al 2003).
Webber et al (1996) synthesized isatin-based inhibi-
tors of human rhinovirus 3C protease, a viral enzyme that 
is absolutely required for the proteolytic cleavage of viral 
precursor polyproteins to functional proteins (Wanga and 
Chen 2007).
Simple N-substituted isatin analogue, N-carbobenzyloxy 
isatin, acted as a slow binding inhibitor of chymotrypsin but 
not of porcine elastase (Iyer and Hanna 1995). N-substituted 
isatins containing complex substituents effectively inhibited 
human serine proteases: chymotrypsin, leukocyte elastase 
and plasmin (Shuttleworth et al 2000).
Caspases
Caspases are a family of cysteine-dependent aspartate-
directed proteases. There are at least 14 caspases known to 
date, which play a signiﬁ  cant role in apoptosis and inﬂ  am-
mation (Earnshaw et al 1999; Yuan and Yankner 2000; 
Troy and Salvesen 2002). Caspases (8 and 9) function as 
“upstream”-initiators of the proteolytic cascade or “down-
stream”-effectors (caspases 3, 6, 7) (Chowdhury et al 2006). 
Recent studies suggest that caspases are also involved in 
many other physiological processes such as immunity and 
cell differentiation, cell cycle, regulatory mechanisms in 
nervous tissue, etc. (Timmer and Salversen 2007; Kuranada 
and Miura 2007). Numerous data show that caspases’ 
cascades take part in the dysfunction and death of neurons 
in neurodegenerative disorders, including Alzheimer’s, 
Parkinson’s and Hantington’s diseases (Earnshaw et al 
1999; Troy and Salvesen 2002; Jellinger 2006; Mattson 
2006; Mehta et al 2007). There is an increasing evidence 
that caspase substrates serve as molecular targets in the 
N
R
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Figure 2 Key positions in the isatin ring used for various substitutions.Biologics: Targets & Therapy 2007:1(2) 158
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damaging mechanisms in pathogenesis of cardio-vascular 
dysfunctions, autoimmune and autoinﬂ  ammatory diseases, 
various forms of cancer, rheumatic, ophthalmologic dys-
functions and many other diseases (Guttenplan et al 2001; 
Hajira et al 2004; Stoneman and Bennett 2004; Hinter et al 
2005; Jin and El-Deiry 2005; De Thonel et al 2005; Rose 
and Martin 2005; Reeve et al 2005; Vermeulen et al 2005; 
Siegel 2006; Timmer and Salversen 2007; Testa and 
Riccioni 2007).
The simple isatin analogue, 5-nitroisatin effectively 
inhibited caspase-7 (Ki 0.29 μM), caspase-3 (Ki 0.50 μM), 
and caspase-6 (Ki 1.6 μM) (Lee et al 2000). SB-281277, a 
speciﬁ  c isatin sulfonamide inhibitor of caspase-3/-7 inhibited 
caspase-3 and -7 with a Ki of 15 and 47 nM, respectively. This 
compound exhibited 100-fold greater selectivity for highly 
homologous caspase-3 and -7 vs all other family members 
except caspase-9 (Ki of 460 nM) (Lee et al 2000). Isatin sul-
fonamides, selective caspases 3/7 inhibitors blocked apoptosis 
in murine bone marrow neutrophils and human chondrocytes 
(Lee et al 2000). SB-281277 prevented the ability of bisphos-
phonate caspase activators (zoledronic acid, clodronate or 
alendronate) to cause the characteristic changes in nuclear 
morphology of rabbit osteoclasts associated with apoptosis 
(Benford et al 2001).
Pyrrolidine and azetidine isatin also acted as caspase 
inhibitors and most of them exhibited high inhibitory potency 
against caspase-3 (IC50 of 5–10 nM) and caspase-7 (IC50 
15–25 nM).
Kinases
Protein kinases constitute a very large family of potential tar-
gets in a variety of diseases. Cyclin-dependent kinases (CDK) 
are positive regulators of cell cycle progression (Morgan 
1997). They are key regulators of embryonic development 
and cancer and several CDK inhibitory drugs are at various 
stages of clinical trials as antitumor agents (Senderowicz 
2003). There is evidence that cyclin-dependent kinases 
(CDK) are major regulators of T cell immunity and toler-
ance (see for review Rowell and Wells 2006; Wells 2007). 
These enzymes represent novel potential targets for therapy 
in autoimmune disease and organ transplantation.
There is evidence that indirubin, originating from the 
dimerization of isatin (see Figure 1) and its derivatives are 
potent inhibitors of CDKs1 (Hoessel et al 1999, Leclerc 
et al 2001). Indirubins exhibit a strong afﬁ  nity for CDKs 
(IC50 values in the range of 50–100 nM) (Hoessel et al 
1999, Leclerc et al 2001). Other kinases (c-Src tyrosine 
kinase, caseine kinase, insulin receptor tyrosine kinase, 
cAMP-dependent protein kinase, cGMP-dependent protein 
kinase, protein kinases C α and β1, c-Raf, MAPK, ERK) 
exhibited much lower sensitivity (IC50 values from 1.5 μM 
and above) (Hoessel et al 1999).
Substituted indirubins, produced by Escherichia coli-
expressed human P450 2A6 mutants cultivated in the pres-
ence of 5-methylindole or 5-methoxyindole inhibited human 
CDK-1 and -5 with IC50 values of 0.4–1.2 μM and glycogen 
synthase kinase-3α/β (Guengerich et al 2004).
Indirubins effectively inhibited glycogen synthase kinase-
3β (GSK-3β) with IC50 values in the 5–50 nM range (Leclerc 
et al 2001). This kinase is involved in multiple physiological 
processes, including cell cycle regulation by controlling the 
levels of cyclin D1 (Diehl et al 1998) and β-catenin (Yost 
et al 1996), insulin effect on glycogen synthesis (Cohen 
1999; Summers et al 1999), axonal outgrowth (Lucas et al 
1998), HIV-1 Tat mediated neurotoxicity (Maggirwar et al 
1999), etc. GSK-3β and CDK5 are responsible for most of the 
abnormal hyperphosphorylation of the microtubule-binding 
protein tau observed in the paired helical ﬁ  laments, which are 
diagnostic for Alzheimer’s disease (AD) (Imahori and Uchida 
1997; Mandelkow and Mandelkow 1998). Thus indirubins 
may constitute a lead compound in the study and treatment 
of neurodegenerative disorders.
The endogenous activity of ERK was significantly 
decreased by treatment with isatin 5-hydroxyoxindole. The 
activity was inhibited in a concentration-dependent man-
ner by both endogenous compounds. Concentrations of 
60 mM were necessary to obtain signiﬁ  cant inhibition with 
5-hydroxyoxindole and isatin (20% and 25%, respectively). 
5-hydroxyoxindole was more active than isatin in inhibition 
of ERK2 phosphorylation. These effects appear to be rather 
selective as both compounds did not inﬂ  uence ERK1 phos-
phorylation (Cane 2000).
Others
Reverse transcriptase, catalyzing the reaction of DNA 
synthesis on RNA template is considered as a promising 
target for anti-HIV drugs (De Clerq 2005; Pauwels 2006). 
Aminopyrimidinimino isatin derivatives inhibited repli-
cation of HIV type 1 in T4 lymphocytes (CEM cell line) 
and especially in MT-4 cells, however, their effectiveness 
was signiﬁ  cantly lower than that of the reference standard 
Nevirapine (Sriram et al 2005). Although in vitro assay 
revealed that the compounds possessing anti-HIV-1 activity 
did inhibit reverse transcriptase; their IC50 values (con-
centration required for 50% inhibition) of 20–40 μM were 
several times higher than their EC50 (effective concentration Biologics: Targets & Therapy 2007:1(2) 159
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required for 50% inhibition) for the cytopathic effect of 
HIV-1 in MT-4 cell culture (Sriram et al 2005). Twelve 
isatin derivatives of this series were also active against 
hepatitis C virus (HCV) RNA replication showing 80% 
inhibition at 50 μg/ml, however, biological targets respon-
sible for this effect have not been investigated (Sriram et al 
2005). N-methylisatin 3-thiosemicarbazone (methisazone, 
Marboran) was effective in the prophylaxis of smallpox. 
In several trials during epidemics, methisazone reduced 
the attack rate by 75 to 95% (De Clerq 2001). Isatin 
3-thiosemicarbazone inhibited vaccina virus multiplication 
in chicken embryo kidney cells or HeLa cells with IC50 value 
1 μg/ml, but in the case of other viruses (monkeypox virus 
and variola virus) the IC50 values were higher (30–60 μg/ml). 
Mechanism of action of isatin 3-thiosemicarbazone remains 
to be clariﬁ  ed, certain evidence exists that it inﬂ  uences with 
viral maturation (De Clerq 2001).
1 μM N-methyl isatin β-thiosemicarbazone (Me-IBT) 
inhibited Rous sarcoma virus RNA-dependent DNA poly-
merase by 50%, whereas in combination with 1 μM CuSO4, 
which caused minor (10%–15%) inhibition, it caused 
nearly total inhibition of the enzyme activity (Levinson 
et al 1973).
The isatin analogues, 5-Fluoroisatin, 5-Chloroisatin, 
6-Chloroisatin, 7-Chloroisatin, and 5-methylisatin, but not 
4-Bromoisatin and 5-Iodoisatin inhibited production of 
nitric oxide and PGE2 TNF-α by RAW 264.7 macrophage 
cells activated by a mixture of lipopolysaccharide (LPS) and 
interferon γ (Matheus et al 2007). However, their effective-
ness insigniﬁ  cantly differed from the effect of isatin. As in 
the case of isatin the inhibition of NO and PGE2 produc-
tion in LPS-INF-γ is obviously associated with the isatin 
effect on expression of inducible nitric oxide synthase and 
cyclooxygenase-2 respectively, as it has been demonstrated 
by a Western blot analysis (Matheus et al 2007). Produc-
tion of TNF-α by the activated cells was decreased by the 
all isatins studied, and 5-iodoisatin exhibited the highest 
effectiveness (Matheus et al 2007). The authors suggest that 
isatin and its analogues may have chemopreventive activity 
against the malignant process by down-regulating COX-2 
and/or iNOS (Matheus et al 2007).
Carboxylesterases are ubiquitous enzymes involved 
into metabolism of various xenobiotics including drugs 
employed clinically (eg, demerol, lidocaine, capecitabine) 
(Lohr et al 1998; Hyatt et al 2007). Isatin analogues 
containing hydrophobic groups attached at a variety of 
positions within these molecules, exhibited potent and 
speciﬁ  c inhibition of carboxylesterases with Ki values in 
the nM range (Hyatt et al 2007). Authors believe that isatin 
analogues may be considered as the lead compounds for 
the development of inhibitors modulating drug metabolism 
in vivo.
Interaction of isatin with its analogues 
and drugs
Although the interaction between isatin and its analogues, 
and drugs at speciﬁ  c biological targets still requires detailed 
analysis, there is evidence that isatin protects MAO B 
against irreversible inhibiton by mechanism based inhibitors 
phenelzine (Panova et al 1997) and pargyline (Medvedev 
et al unpublished observation). Deprenyl in its turn inhibited 
isatin binding to GAPDH and this effect was rather speciﬁ  c 
because the other mechanism based MAO inhibitor, tranyl-
cypromine, was ineffective (Medvedev et al 2006). Deprenyl 
was somewhat more effective in inhibition of RNase activity 
of GAPDH than isatin, and during their combined addition 
the effect of RNase inhibition was somewhat less pronounced 
than in the case of independent action of deprenyl (Medvedev 
et al 2006). Thus it is possible that being less effective than 
the pharmacological drug, deprenyl, isatin may attenuate 
some of its effects.
5-Hydroxyisatin and to a lesser extent N-methylisatin 
inhibited ubiquitin binding to amino-isatin immobilized 
onto a cuvette of optical biosensor Biacore (Buneeva et al in 
preparation). The latter suggests that endogenous isatin may 
attenuate interaction of some biological targets with drugs 
containing isatin moiety and therefore inﬂ  uence expected 
therapeutic effect.
Conclusions
Isatin and its analogues act on a large number of biologi-
cal targets and have a wide variety of actual and potential 
pharmacological actions. There is some evidence that isatin 
may attenuate the effects of certain pharmaceutical agents 
on speciﬁ  c biological targets, such as monoamine oxidase 
inhibitors and/or neuroprotective drugs (Panova et al 1997; 
Medvedev et al 2006). Isatin can be present in blood in 
the micromolar range and increases in response to stress 
(Igosheva et al 2004). This suggests that endogenous isatin, 
and possibly its precursors and metabolites, may affect the 
sensitivity of biological targets to therapeutics employed a 
range of diseases and disorders.
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